search
Back to results

Soy and Isoflavones Effect on Bone

Primary Purpose

Osteoporosis

Status
Completed
Phase
Phase 4
Locations
United States
Study Type
Interventional
Intervention
Soy Isolate
Control protein
Novasoy isoflavones
Placebo tablets
Sponsored by
United States Department of Agriculture (USDA)
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Osteoporosis focused on measuring bone density, bone loss, postmenopausal

Eligibility Criteria

65 Years - undefined (Older Adult)FemaleAccepts Healthy Volunteers

Inclusion Criteria:

  • Postmenopausal women 65 years old or older
  • Able to travel to the clinical sites for follow-up visits

Exclusion Criteria:

  • History of disease that may affect bone metabolism (including Paget's disease, primary hyperparathyroidism, osteomalacia, untreated hyperthyroidism, or multiple myeloma)
  • Cancer of any kind (except basal or squamous cell of skin) in past 5 years
  • Use of any of the following medications within the past 2 years: calcitonin, calcitriol, heparin, phenytoin, phenobarbital
  • Use at any time of bisphosphonates, long-term corticosteroids (over 6 months), methotrexate, or fluoride
  • Estimated creatinine clearance less than 50 ml/min
  • History of chronic liver disease or evidence of liver disease on screening
  • History of hip fracture
  • Known vertebral fracture within the past year
  • Vegans

Sites / Locations

  • University of Connecticut Health Center

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm Type

Experimental

Active Comparator

Active Comparator

Placebo Comparator

Arm Label

1

2

3

4

Arm Description

Soy protein and isoflavone tablets

Soy protein and placebo tablets

control protein and Isoflavone tablets

control protein and placebo tablets

Outcomes

Primary Outcome Measures

Bone turnover markers

Secondary Outcome Measures

Bone Mineral Density
Quality of life measured by Medical Outcomes Short Form
Medication Side Effects
Adherence to dietary intervention through the use of 24-hour recall
Long-term medication behavior self-efficacy scale

Full Information

First Posted
April 25, 2008
Last Updated
April 25, 2008
Sponsor
United States Department of Agriculture (USDA)
Collaborators
University of Connecticut
search

1. Study Identification

Unique Protocol Identification Number
NCT00668447
Brief Title
Soy and Isoflavones Effect on Bone
Official Title
Soy Proteins and Isoflavones Impact Bone Mineral Density in Older Women
Study Type
Interventional

2. Study Status

Record Verification Date
April 2008
Overall Recruitment Status
Completed
Study Start Date
November 2001 (undefined)
Primary Completion Date
June 2005 (Actual)
Study Completion Date
June 2005 (Actual)

3. Sponsor/Collaborators

Name of the Sponsor
United States Department of Agriculture (USDA)
Collaborators
University of Connecticut

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
The purpose of this study is to test the effect of 1 year of added dietary soy protein and/or soy isoflavones on bone mineral density in late postmenopausal women.
Detailed Description
Although soy foods contain several components (isoflavones and amino acids) that could potentially have positive effects on bone health, there are few long term, large, clinical trials using soy as a means of improving bone mineral density. The objective of this study is to provide daily soy protein and isoflavones to healthy older women in order to answer three major questions: Does soy protein alone affect bone metabolism? Do isoflavones, given with soy protein, affect bone metabolism? What dose of isoflavones affects bone in older women? We hypothesize that soy protein will have a beneficial effect on bone in older women compared to control protein. Further, we hypothesize that there will be an additional benefit to bone in women who receive soy protein plus isoflavones (at both doses) compared to soy protein alone. Both control and soy proteins used in the study were isolates, meaning they were the highest concentration of protein (85-90% by weight) in order to minimize the volume of protein supplement that each woman was asked to ingest on a daily basis. The soy protein was an alcohol-washed, soy protein isolate containing 90% protein and negligible isoflavone (0.2 mg/g product). The control protein was a mix consisting of 50% protein from sodium caseinate, 25% protein from whey protein and 25% from egg white protein. The use of a mix of proteins as a control provides a more balanced level of amino acids, mimics the real life mix of proteins that humans typically consume, and avoids the unique characteristics of one source of protein. In order to maintain the dietary protein intake constant, the participant was counseled to decrease her intake of other sources of protein from primarily animal sources by approximately 3 ounces per day (the approximate equivalent of the protein powders). The isoflavones tablets each contained 57 mg of total isoflavone from primarily genistein, glycitein, and daidzein and their beta-glycosides.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Osteoporosis
Keywords
bone density, bone loss, postmenopausal

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Factorial Assignment
Masking
ParticipantInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
97 (Actual)

8. Arms, Groups, and Interventions

Arm Title
1
Arm Type
Experimental
Arm Description
Soy protein and isoflavone tablets
Arm Title
2
Arm Type
Active Comparator
Arm Description
Soy protein and placebo tablets
Arm Title
3
Arm Type
Active Comparator
Arm Description
control protein and Isoflavone tablets
Arm Title
4
Arm Type
Placebo Comparator
Arm Description
control protein and placebo tablets
Intervention Type
Dietary Supplement
Intervention Name(s)
Soy Isolate
Other Intervention Name(s)
Pro Fam 930, 066-930
Intervention Description
20 grams of powder mixed in beverages or food daily for one year
Intervention Type
Dietary Supplement
Intervention Name(s)
Control protein
Intervention Description
20 grams of powder mixed in beverages or food daily for one year
Intervention Type
Dietary Supplement
Intervention Name(s)
Novasoy isoflavones
Intervention Description
3 tablets daily for one year
Intervention Type
Dietary Supplement
Intervention Name(s)
Placebo tablets
Intervention Description
3 tablets daily for one year
Primary Outcome Measure Information:
Title
Bone turnover markers
Time Frame
baseline, 3 months, and 1 year
Secondary Outcome Measure Information:
Title
Bone Mineral Density
Time Frame
Baseline, 6 and 12 months
Title
Quality of life measured by Medical Outcomes Short Form
Time Frame
Baseline, 6 and 12 months
Title
Medication Side Effects
Time Frame
3 , 6, 9, and 12 months
Title
Adherence to dietary intervention through the use of 24-hour recall
Time Frame
3, 6, 9, and 12 months
Title
Long-term medication behavior self-efficacy scale
Time Frame
3, 6, 9, and 12 months

10. Eligibility

Sex
Female
Minimum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Postmenopausal women 65 years old or older Able to travel to the clinical sites for follow-up visits Exclusion Criteria: History of disease that may affect bone metabolism (including Paget's disease, primary hyperparathyroidism, osteomalacia, untreated hyperthyroidism, or multiple myeloma) Cancer of any kind (except basal or squamous cell of skin) in past 5 years Use of any of the following medications within the past 2 years: calcitonin, calcitriol, heparin, phenytoin, phenobarbital Use at any time of bisphosphonates, long-term corticosteroids (over 6 months), methotrexate, or fluoride Estimated creatinine clearance less than 50 ml/min History of chronic liver disease or evidence of liver disease on screening History of hip fracture Known vertebral fracture within the past year Vegans
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Jane Kerstetter, PhD
Organizational Affiliation
Department of Allied Health Sciences, University of Connecticut
Official's Role
Principal Investigator
Facility Information:
Facility Name
University of Connecticut Health Center
City
Farmington
State/Province
Connecticut
ZIP/Postal Code
06030
Country
United States

12. IPD Sharing Statement

Citations:
PubMed Identifier
17213752
Citation
Evans EM, Racette SB, Van Pelt RE, Peterson LR, Villareal DT. Effects of soy protein isolate and moderate exercise on bone turnover and bone mineral density in postmenopausal women. Menopause. 2007 May-Jun;14(3 Pt 1):481-8. doi: 10.1097/01.gme.0000243570.78570.f7.
Results Reference
background
PubMed Identifier
10966908
Citation
Alekel DL, Germain AS, Peterson CT, Hanson KB, Stewart JW, Toda T. Isoflavone-rich soy protein isolate attenuates bone loss in the lumbar spine of perimenopausal women. Am J Clin Nutr. 2000 Sep;72(3):844-52. doi: 10.1093/ajcn/72.3.844.
Results Reference
background
PubMed Identifier
15727682
Citation
Arjmandi BH, Lucas EA, Khalil DA, Devareddy L, Smith BJ, McDonald J, Arquitt AB, Payton ME, Mason C. One year soy protein supplementation has positive effects on bone formation markers but not bone density in postmenopausal women. Nutr J. 2005 Feb 23;4:8. doi: 10.1186/1475-2891-4-8.
Results Reference
background
PubMed Identifier
19474141
Citation
Kenny AM, Mangano KM, Abourizk RH, Bruno RS, Anamani DE, Kleppinger A, Walsh SJ, Prestwood KM, Kerstetter JE. Soy proteins and isoflavones affect bone mineral density in older women: a randomized controlled trial. Am J Clin Nutr. 2009 Jul;90(1):234-42. doi: 10.3945/ajcn.2009.27600. Epub 2009 May 27.
Results Reference
derived

Learn more about this trial

Soy and Isoflavones Effect on Bone

We'll reach out to this number within 24 hrs